Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NKTR Stock Forecast 2026-2027
$77.85
Current Price
$2.23B
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NKTR Price Targets
+111.9%
To High Target of $165.00
+68.9%
To Median Target of $131.50
-10.1%
To Low Target of $70.00
NKTR Price Momentum
+1.1%
1 Week Change
+8.0%
1 Month Change
+938.0%
1 Year Change
+84.1%
Year-to-Date Change
-1.2%
From 52W High of $78.81
+1,107.0%
From 52W Low of $6.45
📊 TOP ANALYST CALLS
Did NKTR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nektar is one of their latest high-conviction picks.
Latest NKTR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, NKTR has a bullish consensus with a median price target of $131.50 (ranging from $70.00 to $165.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $77.85, the median forecast implies a 68.9% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Arthur He at HC Wainwright & Co., projecting a 111.9% upside. Conversely, the most conservative target is provided by Martin Fan at Wedbush, suggesting a 10.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NKTR Analyst Ratings
9
Buy
1
Hold
0
Sell
NKTR Price Target Range
Low
$70.00
Average
$131.50
High
$165.00
Current: $77.85
Latest NKTR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NKTR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 24, 2026 | Wedbush | Martin Fan | Neutral | Initiates | $70.00 |
| Mar 17, 2026 | TD Cowen | Marc Frahm | Buy | Initiates | $N/A |
| Mar 16, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $123.00 |
| Feb 23, 2026 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $150.00 |
| Feb 10, 2026 | BTIG | Julian Harrison | Buy | Maintains | $151.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $165.00 |
| Jan 29, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $118.00 |
| Dec 16, 2025 | BTIG | Julian Harrison | Buy | Maintains | $118.00 |
| Dec 16, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $135.00 |
| Nov 26, 2025 | Jefferies | Roger Song | Buy | Maintains | $121.00 |
| Nov 26, 2025 | Citigroup | Samantha Semenkow | Buy | Initiates | $102.00 |
| Sep 23, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $105.00 |
| Sep 19, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $100.00 |
| Jul 8, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $85.00 |
| Jun 24, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $120.00 |
| Apr 11, 2025 | Jefferies | Roger Song | Buy | Upgrade | $2.00 |
| Mar 14, 2025 | Oppenheimer | Jay Olson | Outperform | Upgrade | $6.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.50 |
| Feb 25, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.50 |
| Jan 13, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.50 |
Nektar Therapeutics Inc. (NKTR) Competitors
The following stocks are similar to Nektar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nektar Therapeutics Inc. (NKTR) Financial Data
Nektar Therapeutics Inc. has a market capitalization of $2.23B with a P/E ratio of -8.0x. The company generates $55.23M in trailing twelve-month revenue with a -297.1% profit margin.
Revenue growth is -25.3% quarter-over-quarter, while maintaining an operating margin of -87.5% and return on equity of -217.9%.
Valuation Metrics
Market Cap
$2.23B
Enterprise Value
$2.14B
P/E Ratio
-8.0x
PEG Ratio
0.0x
Price/Sales
40.4x
Growth & Margins
Revenue Growth (YoY)
-25.3%
Gross Margin
+100.0%
Operating Margin
-87.5%
Net Margin
-297.1%
EPS Growth
-25.3%
Financial Health
Cash/Price Ratio
+11.0%
Current Ratio
5.0x
Debt/Equity
165.8x
ROE
-217.9%
ROA
-28.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nektar Therapeutics Inc. (NKTR) Business Model
About Nektar Therapeutics Inc.
What They Do
Develops immune-modulating therapies for autoimmune diseases.
Business Model
Nektar Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of therapies that modulate the immune system. The company generates revenue primarily through research and development activities, including clinical trials for its lead product, rezpegaldesleukin, which is currently in Phase 2b trials. Additionally, Nektar explores partnerships and collaborations for its investigational programs targeting various immune pathways.
Additional Information
Founded in 1990 and based in San Francisco, Nektar Therapeutics leverages its expertise in polymer chemistry and immunology to create innovative treatments for unmet medical needs. The company has a diverse pipeline that includes multiple candidates aimed at treating chronic inflammatory diseases and enhancing anti-tumor responses in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
63
CEO
Mr. Howard W. Robin
Country
United States
IPO Year
1994
Website
www.nektar.comNektar Therapeutics Inc. (NKTR) Latest News & Analysis
Latest News
Quick Summary
A class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) for securities violations. Investors who purchased shares between Feb 26, 2025, and Dec 15, 2025, should contact Schall Law Firm by May 5, 2026.
Why It Matters
A class action lawsuit against Nektar Therapeutics for securities violations may indicate potential legal and financial risks, impacting shareholder value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi is investigating claims against Nektar Therapeutics (NASDAQ: NKTR) for investors who suffered losses from February 26 to December 15, 2025. Deadline for lead plaintiff role is May 5, 2026.
Why It Matters
Nektar is facing a federal securities class action, which could indicate potential financial liabilities. This may affect stock performance, impacting current and prospective investors.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm notifies Nektar Therapeutics (NASDAQ: NKTR) investors that the lead plaintiff deadline for securities purchased between Feb 26, 2025, and Dec 15, 2025, is May 5, 2026.
Why It Matters
The announcement highlights a class action lawsuit involving Nektar Therapeutics, potentially impacting share prices and investor sentiment ahead of the May 5 deadline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm reminds Nektar Therapeutics (NASDAQ: NKTR) investors who bought shares from Feb 26 to Dec 15, 2025, of a May 5, 2026 lead plaintiff deadline for potential compensation.
Why It Matters
Pending litigation could impact Nektar Therapeutics' stock price and investor sentiment, potentially affecting market valuations and future investment decisions.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts Nektar Therapeutics (NASDAQ: NKTR) investors who bought shares between Feb 26 and Dec 15, 2025, of a May 5, 2026, deadline to seek compensation at no upfront cost.
Why It Matters
The announcement of a lead plaintiff deadline could indicate potential legal liabilities for Nektar Therapeutics, impacting investor sentiment and stock price.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) for alleged violations of securities laws. Affected shareholders are encouraged to contact DJS Law Group for lead plaintiff opportunities.
Why It Matters
A class action lawsuit against Nektar Therapeutics for securities violations could lead to financial penalties and impact share prices, influencing investor sentiment and market value.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NKTR Stock
What is Nektar Therapeutics Inc.'s (NKTR) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Nektar Therapeutics Inc. (NKTR) has a median price target of $131.50. The highest price target is $165.00 and the lowest is $70.00.
Is NKTR stock a good investment in 2026?
According to current analyst ratings, NKTR has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $77.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NKTR stock?
Wall Street analysts predict NKTR stock could reach $131.50 in the next 12 months. This represents a 68.9% increase from the current price of $77.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nektar Therapeutics Inc.'s business model?
Nektar Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of therapies that modulate the immune system. The company generates revenue primarily through research and development activities, including clinical trials for its lead product, rezpegaldesleukin, which is currently in Phase 2b trials. Additionally, Nektar explores partnerships and collaborations for its investigational programs targeting various immune pathways.
What is the highest forecasted price for NKTR Nektar Therapeutics Inc.?
The highest price target for NKTR is $165.00 from Arthur He at HC Wainwright & Co., which represents a 111.9% increase from the current price of $77.85.
What is the lowest forecasted price for NKTR Nektar Therapeutics Inc.?
The lowest price target for NKTR is $70.00 from Martin Fan at Wedbush, which represents a -10.1% decrease from the current price of $77.85.
What is the overall NKTR consensus from analysts for Nektar Therapeutics Inc.?
The overall analyst consensus for NKTR is bullish. Out of 20 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $131.50.
How accurate are NKTR stock price projections?
Stock price projections, including those for Nektar Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 11:40 AM UTC